Top Stories
Pfizer patent settlements extend Vyndamax exclusivity to 2031, protecting $6.4B rare disease franchise from generic competition
On April 28, 2026, Pfizer announced settlement agreements with generic manufacturers Dexcel Pharma, Hikma Pharmaceuticals, and Cipla to extend the effective US patent life for Vyndamax (tafamidis) in transthyretin amyloid cardiomyopathy (ATTR-CM) to June 1, 2031, as reported by BioPharma Dive. Pfizer had previously anticipated a significant revenue decline beginning in 2029 upon original patent expiry; the tafamidis franchise generated $6.38 billion in 2025 revenue, according to Pharmaceutical Technology, making it Pfizer's largest rare disease asset. Vyndamax holds approximately 75% of prescription volume in the ATTR-CM market, according to Pfizer. Pfizer discontinued the lower-dose Vyndaqel formulation in the US as of December 31, 2025, consolidating the franchise under the Vyndamax brand. ATTR-CM is a rare but increasingly diagnosed condition; published prevalence estimates vary widely, and many patients remain undiagnosed. The settlements do not resolve all patent litigation — a case with Apotex Corp. remains pending in the US District Court for the District of Delaware. The extended exclusivity window defines the competitive timeline for gene silencing approaches from Alnylam (patisiran, vutrisiran) and gene editing programs targeting TTR, which are earlier in development. The settlements also have implications for BridgeBio, whose acoramidis (Attruby) is the primary branded competitor in the ATTR-CM space, as extended Vyndamax exclusivity defines the competitive landscape through 2031.
Chiesi acquires KalVista for $1.9B, consolidating oral HAE therapy Ekterly into its rare disease platform
On April 29, 2026, Chiesi Group agreed to acquire KalVista Pharmaceuticals for $1.9 billion ($27.00 per share, a 36% premium to KalVista's 30-day VWAP), adding Ekterly (sebetralstat), the first FDA-approved oral on-demand treatment for hereditary angioedema attacks, to its rare disease portfolio, as BioPharma Dive reported. The transaction, expected to close in Q3 2026, was unanimously approved by both boards, according to KalVista investor relations. MedCity News observed that this is the fifth biotech acquisition of the week, reflecting sustained pharma appetite for oral HAE therapies. Ekterly, which received FDA approval in 2025, is differentiated as an on-demand acute treatment rather than a prophylactic, positioning it complementarily alongside chronic prophylaxis options such as lanadelumab and berotralstat. Chiesi, a private Italian pharmaceutical group with existing rare disease infrastructure, appears to be building scale in HAE by combining Ekterly commercial momentum with its established patient access capabilities. The $1.9 billion valuation implies acquirer confidence in Ekterly durable revenue potential, and Chiesi has indicated that sebetralstat is expected to contribute meaningfully to its 2030 revenue target. BD teams tracking HAE deal flow should note that this acquisition reduces the number of independent oral HAE assets available for licensing or partnering.
Rocket Pharmaceuticals sells priority review voucher for $180M following Kresladi gene therapy approval
On April 28, 2026, Rocket Pharmaceuticals entered a definitive agreement to sell its FDA rare pediatric disease priority review voucher for $180 million, following the accelerated approval of Kresladi (marnetegragene autotemcel) on March 26, 2026 as the first gene therapy for severe leukocyte adhesion deficiency type I (LAD-I), according to Fierce Pharma. The accelerated approval is based on increases in neutrophil CD18 and CD11a cell surface expression as a surrogate endpoint reasonably likely to predict clinical benefit; continued approval may be contingent upon confirmatory data. Pharmaceutical Executive also reported the transaction, noting it reflects sustained buyer demand for instruments that shorten FDA review timelines by approximately six months. The $180 million price point is broadly consistent with recent PRV transaction history. For Rocket, the proceeds extend cash runway into Q2 2028, according to Rocket investor relations, and support its broader gene therapy pipeline including programs in Fanconi anemia and pyruvate kinase deficiency. PRV monetization has become a structural component of the rare pediatric disease development economics, effectively subsidizing the cost of orphan program development for smaller biotechs.
Pipeline Watch
Danish dermatology company Leo Pharma paid $50 million to acquire US gene writing biotech Replay and its preclinical gene therapy program for a rare skin disease, as Fierce Biotech reported. The deal gives Leo Pharma a gene therapy capability and a potential one-time treatment option to complement its small molecule and biologic dermatology portfolio. The program remains preclinical, so clinical proof-of-concept and manufacturing scale-up timelines are not yet established.
In an April 27, 2026 letter, the FDA's CDER notified Amgen it is proposing to withdraw approval of Tavneos (avacopan) for ANCA-associated vasculitis, citing new information indicating that unblinded study personnel manipulated results of the pivotal ADVOCATE trial, and that the applicant (ChemoCentryx, now an Amgen subsidiary) did not disclose the original analysis to the FDA, per Fierce Pharma. The FDA also identified 76 post-marketing cases of drug-induced liver injury, including 8 deaths, according to the FDA statement. Amgen informed the FDA on January 28, 2026 that it does not intend to voluntarily withdraw Tavneos from the market. This action raises questions about post-marketing surveillance rigor and the integrity of approval data packages for rare disease drugs.
Neurogene announced a presentation at the upcoming ASGCT annual meeting covering the therapeutic rationale for intracerebroventricular delivery in CNS-targeted gene therapy, with safety and efficacy data from NGN-401 in Rett syndrome featured, according to Neurogene IR. ICV delivery offers broad biodistribution to brain and nervous system tissue and is positioned as a routine neurosurgical procedure. Rett syndrome affects approximately 6,000 to 9,000 US patients according to published prevalence estimates, primarily females, with no approved disease-modifying therapies currently available.
Competitive Landscape
The HAE market is now contested across four distinct modalities: subcutaneous biologics, oral small molecules, RNA interference, and in vivo gene editing. Chiesi Ekterly acquisition and Intellia lonvo-z BLA filing in the same period signals that both chronic and one-time therapy strategies are advancing simultaneously, raising questions about patient segmentation and payer willingness to fund curative-intent therapies at premium pricing.
| Therapy | Modality | Status | Owner |
|---|---|---|---|
| Lonvo-z | In vivo CRISPR | BLA Filed (Rolling) | Intellia |
| Ekterly (sebetralstat) | Oral on-demand kallikrein inhibitor | FDA Approved 2025 | Chiesi / KalVista |
| Takhzyro (lanadelumab) | Subcutaneous biologic | Approved | Takeda |
| Orladeyo (berotralstat) | Oral kallikrein inhibitor | Approved | BioCryst |
Rocket Pharmaceuticals monetized its post-approval PRV for $180 million in non-dilutive proceeds, while Leo Pharma deployed $50 million to acquire preclinical gene writing capability via Replay. Both transactions illustrate that rare disease gene therapy value creation is occurring across the full development continuum, from preclinical platform acquisition to post-approval financial instrument monetization.
Forward Looking
- The Apotex patent litigation outcome will determine whether the Pfizer Vyndamax exclusivity extension to June 1, 2031 holds; a different result could reopen the generic entry window and reshape competitive dynamics in ATTR-CM for Alnylam, BridgeBio, and gene editing programs targeting TTR.
- Chiesi/KalVista transaction expected to close in Q3 2026; integration of Ekterly US commercial operations into Chiesi's rare disease platform will be the next operational milestone.
- Neurogene NGN-401 ASGCT data presentation will offer early clinical signals on ICV delivery tolerability for CNS gene therapy, relevant to multiple programs targeting rare pediatric neurological diseases.
- FDA response to Amgen on the Tavneos proposed rescission will clarify the procedural pathway for approval withdrawals based on post-approval data integrity findings, with implications for rare disease regulatory risk modeling.
- Leo Pharma Replay integration timelines and IND-enabling study initiation for the rare skin disease gene therapy program will indicate how quickly the preclinical asset can advance toward clinical proof-of-concept.